(Q39349073)

11 September 2017

Implications of the CATIE trial on treatment: extrapyramidal symptoms (English)

1 reference

11 September 2017

Daniel E Casey

1

1 reference

11 September 2017

1 July 2006

1 reference

11 September 2017

1 reference

11 September 2017

11

1 reference

11 September 2017

25-31

1 reference

11 September 2017

7 Suppl 7

1 reference

The Barnes Akathisia Rating Scale--revisited

11 September 2017

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Research Diagnoses for Tardive Dyskinesia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Diabetes and development of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Tardive dyskinesia in psychiatric patients with substance use disorders.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Sub-syndromes of tardive dyskinesia and some clinical correlates

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Safety and tolerability: how do newer generation "atypical" antipsychotics compare?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Prospective study of tardive dyskinesia in the elderly: rates and risk factors

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Increased tardive dyskinesia in alcohol-abusing schizophrenic patients

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Gender differences in tardive dyskinesia: a critical review of the literature

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Tardive dyskinesias and antipsychotics: a review

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Tardive dyskinesia and atypical antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Generating evidence to inform policy and practice: the example of the second generation "atypical" antipsychotics

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Diabetes, tardive dyskinesia, parkinsonism, and akathisia in schizophrenia: a retrospective study applying 1998 diabetes health care guidelines to antipsychotic use.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Dropout rates in randomised antipsychotic drug trials

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026651

7 January 2021

10.1017/S1092852900026651

Identifiers

DOI

0 references

PubMed ID

16816797

1 reference

PubMed ID

16816797